Thomas Auxter
Family Medicine · Venice, FLNPI 1902865470
Payments from drug & device makers
Across 275 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$590
- AstraZeneca$469
- Johnson & Johnson$458
- Amarin Pharma, Inc.$299
- Lilly USA, LLC$275
- Amgen$266
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,647100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $590 |
| AstraZeneca | 21 | $469 |
| Johnson & Johnson | 9 | $458 |
| Amarin Pharma, Inc. | 12 | $299 |
| Lilly USA, LLC | 23 | $275 |
| Amgen(2 entities) | 18 | $266 |
| Pfizer | 21 | $262 |
| AbbVie(2 entities) | 6 | $248 |
| GSK | 18 | $238 |
| Sanofi-aventis U.S. LLC | 9 | $219 |
| Boehringer Ingelheim | 13 | $198 |
| Teva Pharmaceuticals USA, Inc. | 5 | $169 |
| Merck | 17 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $112 |
| Kowa Pharmaceuticals America, Inc. | 7 | $97 |
| Astellas Pharma US Inc | 6 | $92 |
| Sunovion Pharmaceuticals Inc. | 10 | $79 |
| Novartis | 5 | $76 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Avanir Pharmaceuticals, Inc. | 3 | $35 |
| Antares Pharma, Inc. | 2 | $27 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| Boston Scientific | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,654 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $90,935 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $40,702 |
| Celecoxib | 176 | $33,840 |
| OzempicSemaglutide | 28 | $23,795 |
| EntrestoSacubitril/Valsartan | 14 | $17,266 |
| XareltoRivaroxaban | 17 | $14,597 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,812 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $4,319 |
| Pregabalin | 22 | $3,787 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $3,196 |
| Gabapentin | 91 | $3,125 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,834 |
| LantusInsulin Glargine,hum.Rec.Anlog | 24 | $2,210 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,198 |
| Duloxetine Hcl | 33 | $2,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $90,93580 claims |
| GSKTrelegy Ellipta | $238 | $40,70241 claims |
| Novo NordiskOzempic | $590 | $23,79528 claims |
| NovartisEntresto | $76 | $17,26614 claims |
| Johnson & JohnsonXarelto | $458 | $14,59717 claims |
| AstraZenecaSymbicort | $469 | $2,83412 claims |
| Sanofi-aventis U.S. LLCLantus | $219 | $2,21024 claims |
| AbbVieSynthroid | $248 | $98316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Venice
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.